Bioline RX Ltd  

(Public, NASDAQ:BLRX)   Watch this stock  
Find more results for BLRX
0.00 (0.00%)
Oct 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.33 - 1.40
52 week 1.26 - 3.34
Open 1.36
Vol / Avg. 49,927.00/63,409.00
Mkt cap 46.40M
P/E     -
Div/yield     -
EPS     -
Shares 1.00
Beta 2.88
Inst. own     -
Jan 12, 2015
BioLine RX Ltd at EBD Biotech Showcase Add to calendar
Jan 12, 2015
BioLine RX Ltd at JPMorgan Healthcare Conference Add to calendar
Nov 10, 2014
Q3 2014 BioLine RX Ltd Earnings Release (Estimated) Add to calendar
Oct 18, 2014
BioLine RX Ltd will present BL-7040 program at the UEG Week 2014
Oct 8, 2014
BioLine RX Ltd will present BL-5010 program at the 23rd EADV Congress
Oct 8, 2014
BioLine RX Ltd will present BL-5010 program at the 23rd EADV Congress
Sep 21, 2014
BioLine RX Ltd Annual Shareholders Meeting
Sep 17, 2014
BioLine RX Ltd will present at the Second Annual Meeting of the Society of Hematologic Oncology (SOHO)
Sep 10, 2014
BioLine RX Ltd at Rodman & Renshaw Global Investment Conference - Webcast
Aug 6, 2014
Q2 2014 BioLine RX Ltd Earnings Call - Webcast
More events from DailyFinance »    


19 Hartum Street, P.O.Box 45158
+972-2-5489100 (Phone)
+972-2-5489101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Officers and directors

Aharon Schwartz Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Kinneret Savitsky Ph.D. Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Philip A. Serlin Chief Financial Officer, Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
Moshe Phillip M.D. Vice President of Medical Affairs and Senior Clinical Advisor
Age: 59
Bio & Compensation  - Reuters
David Malek Vice President - Business Development
Age: 35
Bio & Compensation  - Reuters
Leah Klapper General Manager, BioLine Innovations Jerusalem
Bio & Compensation  - Reuters
Michael J. Anghel Director
Age: 75
Bio & Compensation  - Reuters
Jacob Friedman Director
Age: 44
Bio & Compensation  - Reuters
Raphael Hofstein Director
Age: 63
Bio & Compensation  - Reuters
Sandra Panem Ph.D. Director
Age: 67
Bio & Compensation  - Reuters